AgingResearch.NewsJoin free

Recombinant transthyretin

Intervention

1 paper2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funder: National Natural Science Foundation of China
  • Model organisms1

Outcomes

2

Lifespan

upin worms1

1 study

  1. Recombinant transthyretin extends lifespan in worms (+5 days).

    “TTR-7R increased cultured cell viability from 62% to 89%, scavenged amyloid plaques in AD nematodes, and prolonged nematode lifespan by 5 d at 2 μM.”

    Model organismsAD nematodesTTR-7R2 μM

    Cationic Surface Charge Engineering of Recombinant Transthyretin Remarkably Increases the Inhibitory Potency Against Amyloid β-Protein Fibrillogenesis

    Molecules (Basel, Switzerland)24 Oct 2024

Amyloid plaques

downin worms1

1 study

  1. Recombinant transthyretin decreases amyloid plaques in worms.

    “TTR-7R increased cultured cell viability from 62% to 89%, scavenged amyloid plaques in AD nematodes”

    Model organismsAD nematodesTTR-7R

    Cationic Surface Charge Engineering of Recombinant Transthyretin Remarkably Increases the Inhibitory Potency Against Amyloid β-Protein Fibrillogenesis

    Molecules (Basel, Switzerland)24 Oct 2024

Latest

Related